Ann: Opthea's OPT-302 Granted Fast-Track for wet AMD, page-45

You can find that information in the Annual Report.

Opthea owns a patent family covering the OPT‑302 molecule, and uses thereof, extending out to February 2034. This patent has been filed in 19 jurisdictions and has already granted in the United States, Europe (validated in 38 countries), Japan, Australia, New Zealand, Malaysia, Singapore, Mexico, South Africa, Colombia and Russia. The patent application has been accepted for grant in Canada and Israel, and is currently pending in China, Brazil, India, South Korea, Indonesia and the Philippines.

The United States patent, which granted in August 2017, includes broad claims to the OPT‑302 molecule, and analogues thereof, and their use to treat disorders involving neovascularisation, including eye diseases such as wet AMD and DME. In the United States, Opthea has another granted patent relating to solubleVEGFR‑3 molecules which includes composition of matter claims to soluble VEGFR‑3 molecules (such as OPT ‑302) and extends out to November 2026.